Tech Transfer Central
Industry-Sponsored Research Management

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts

Published by CurrentPartnering
Format: PDF, CD-Rom
Publication Date: March 2015
659 pages

Share:
Twitter Facebook Linkedin Pinterest Email
Price: Starting at $1,995
order button view cart

Global Cancer Monoclonal Antibody PartneringThe Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer monoclonal antibody partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value

The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 250 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of the report provide an orientation of cancer monoclonal dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.

A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the cancer monoclonal antibody field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2010.

Chapter 4 covers the leading cancer monoclonal antibody deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active cancer monoclonal antibody deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.

Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the Cancer monoclonal antibody partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements deals and alliances database.

Chapter 6 brings the report to a conclusion by looking ahead to the future of cancer monoclonal antibody partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.

In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the cancer monoclonal antibody field preparing them with everything they need to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.

A full appendix is provided at the very end of the report which lists all the cancer monoclonal antibody deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged.  The appendix is useful for looking at all the deals signed by one specific company. 

Report scope

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

 Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts includes:

  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
  • Analysis of cancer monoclonal antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 250 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2009

In  Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The  Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 250 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
order button
view cart


Click here for a printable order form